Back to Clinical Trials Overview

Back To Cancer Clinical Trials

Your search for "Genitourinary" returned 10 results:


Phase II Trial to Evaluate Benefit of Early Switch from first-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the opposite sequence, exploring molecular markers and mechanisms of taxane resistance in men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have not received prior chemotherapy
Principal Investigator(s): Che-Kai Tsao

Multi-center Phase 2 Trial of Single-agent Amrubicin as second-line therapy in patients with Advanced/Metastatic Refractory Urothelial Carcinoma
Principal Investigator(s): Matthew Galksy

A Randomized, Phase 2, Open Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma
Principal Investigator(s): Simon J. Hall

Phase II Trial of Everolimus or Everolimus plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma
Principal Investigator(s): Matthew Galsky

A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer
Principal Investigator(s): Matthew Galsky

Phase II Trial of Gemcitabine, Cisplatin, plus Ipilimumab as First-line Treatment for Patients with Metastatic Urothelial Carcinoma
Principal Investigator(s): Matthew Galsky

Metformin - Rising PSA Remote Trial (M-RePoRT)
Principal Investigator(s): Dr. Matthew Galsky

An International Phase 3, Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
Principal Investigator(s): Michael A. Palese

A Pilot Study of Abiraterone Acetate in African American/Black Patients with Castration Resistant Prostate Cancer
Principal Investigator(s): Matthew Galsky

ARMOR2: A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer
Principal Investigator(s): Matthew Galsky